Peptide analogues of a subdominant epitope expressed in ebv-associated tumors: synthesis and immunological activity.
H-Cys-Leu-Gly-Gly-Leu-Leu-Thr-Met-Val-OH (CLG) peptide is an EBV subdominant epitope that represents the target of HLA-A2 restricted CTL responses. The CLG peptide has low affinity for HLA-A2 and does not produce stable complexes, both factors that determine weak CTL responses. In contrast, the [Tyr(1), Ala(3)]CLG (YLA) analogue showed high affinity for HLA-A2 molecules and efficiently stimulated CLG-specific CTL precursors. Nevertheless, this modified epitope showed low enzymatic stability. To further improve the immunotherapeutical potential of this "improved epitope", we have synthesized and tested YLA analogues containing different modifications next to the scissile peptide bond. Among the analogues we found three peptides, with higher enzymatic resistance, that efficiently stimulate CTL responses. These peptides may be used for EBV-specific immunotherapies.
Marastoni
M
M
Department of Pharmaceutical Sciences and Biotechnology Center, University of Ferrara, I-44100 Ferrara, Italy. mru@dns.unife.it
Bazzaro
M
M
Micheletti
F
F
Gavioli
R
R
Tomatis
R
R
D000956:Antigens, Viral / Q000737:chemistry*; D002460:Cell Line; D000939:Epitopes; D019084:Fluorescent Antibody Technique, Indirect; D015789:HLA-A2 Antigen / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000737:chemistry*; D006801:Humans; D006868:Hydrolysis; D009369:Neoplasms / Q000276:immunology* / Q000821:virology; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D010446:Peptide Fragments / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology
D000956:Antigens, Viral; D000939:Epitopes; D015789:HLA-A2 Antigen; D009842:Oligopeptides; D010446:Peptide Fragments; C430903:tyrosyl-leucyl-alanyl-glycyl-glycyl-leucyl-leucyl-threonyl-methionyl-valine